This Article Full Text Full Text (PDF) All Versions of this Article: 37/1/139    most recent 01.STR.0000195182.67656.eev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diener, H.-C. Search for Related Content PubMed PubMed Citation Articles by Diener, H.-C. Related Collections Deep vein thrombosis Heparin Acute Cerebral Infarction Anticoagulants

(Stroke. 2006;37:139.)
© 2006 American Heart Association, Inc.

Original Contributions

Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin

Results of the PROTECT Trial

Hans-Christoph Diener, MD; Erich B. Ringelstein, MD; Rüdiger von Kummer, MD; Helmut Landgraf, MD; Klaus Koppenhagen, MD; Job Harenberg, MD; Ivan Rektor, MD; Attila Csányi, MD; Dietmar Schneider, MD; Jürgen Klingelhöfer, MD; Joachim Brom, PhD; Gottfried Weidinger, PhD for the PROTECT Trial Group

From the University of Essen, Germany (H.C.D.), University of Münster, Germany (E.B.R.); Technical University of Dresden, Germany (R.v.K.); Hospital Friedrichshain, Berlin, Germany (H.L.); Benjamin Franklin Hospital, Berlin, Germany (K.K.); University of Mannheim, Germany (J.H.); Faculty Hospital, Brno, Czech Republic (I.R.); Petz Aladár County Hospital, Györ, Hungary (A.C.); University of Leipzig, Germany (D.S.); Hospital Chemnitz, Germany (J.K.); and Novartis Pharma, Nürnberg, Germany (J.B., G.W.).

Correspondence to Hans-Christoph Diener, MD, PhD, Neurologische Klinik und Poliklinik, Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany. E-mail h.diener{at}uni-essen.de

Background and Purpose— Patients with stroke are at substantial risk of thromboembolic complications and therefore require antithrombotic prophylaxis. To show the noninferiority of the low-molecular-weight heparin certoparin to unfractionated heparin (UFH) for the prevention of thromboembolic complications, we performed a randomized, double-blind, active-controlled multicenter trial in patients with acute ischemic stroke.

Methods— Overall, 545 patients were randomized within 24 hours of stroke onset to treatment with certoparin (3000 U anti-Xa OD; n=272) or UFH (5000 U TID; n=273) for 12 to 16 days. Patients with paresis of a leg and an National Institutes of Health Stroke Scale score of 4 to 30 points were included. The primary end point was a composite outcome of proximal deep vein thrombosis, pulmonary embolism, or death related to venous thromboembolism during treatment. Computed tomography was performed at trial entry, after 7 days, and when clinical deterioration occurred.

Results— The per-protocol analysis revealed 17 (7.0%) primary events in the certoparin group compared with 24 (9.7%) in the UFH group, thereby demonstrating noninferiority (P=0.0011), confirmed by intention-to-treat analysis (6.6% versus 8.8%; P=0.008). Major bleeding occurred during treatment in 3 patients allocated to certoparin (1.1%) and 5 patients allocated to UFH (1.8%).

Conclusions— Certoparin (3000 U anti-Xa OD) is at least as effective and safe as UFH (TID) for the prevention of thromboembolic complications in patients with acute ischemic stroke.

Key Words: cerebrovascular accident • heparin • venous thrombosis

This article has been cited by other articles:

				C. S. Kase, G. W. Albers, C. Bladin, C. Fieschi, A. A. Gabbai, W. O'Riordan, G. F. Pineo, and on behalf of the PREVAIL Investigators Neurological Outcomes in Patients With Ischemic Stroke Receiving Enoxaparin or Heparin for Venous Thromboembolism Prophylaxis: Subanalysis of the Prevention of VTE After Acute Ischemic Stroke With LMWH (PREVAIL) Study Stroke, November 1, 2009; 40(11): 3532 - 3540. [Abstract] [Full Text] [PDF]

				G. F. Pineo and R. D. Hull Economic and Practical Aspects of Thromboprophylaxis With Unfractionated and Low-Molecular-Weight Heparins in Hospitalized Medical Patients Clinical and Applied Thrombosis/Hemostasis, October 1, 2009; 15(5): 489 - 500. [Abstract] [PDF]

				M.-C. Tseng, P. Sandercock, C. Counsell, A. F. Shorr, W. L. Jackson Jr, and L. K. Moores Anticoagulants for Acute Ischemic Stroke Chest, August 1, 2008; 134(2): 466 - 467. [Full Text] [PDF]

				G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]

				A. F. Shorr, W. L. Jackson, J. H. Sherner, and L. K. Moores Differences Between Low-Molecular-Weight and Unfractionated Heparin for Venous Thromboembolism Prevention Following Ischemic Stroke: A Metaanalysis Chest, January 1, 2008; 133(1): 149 - 155. [Abstract] [Full Text] [PDF]

				L. Wein, S. Wein, S. J. Haas, J. Shaw, and H. Krum Pharmacological Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients: A Meta-analysis of Randomized Controlled Trials Arch Intern Med, July 23, 2007; 167(14): 1476 - 1486. [Abstract] [Full Text] [PDF]